Zenas BioPharma, Inc. (ZBIO) Stock Analysis

Q: What is the ZBIO stock price target?

Take-profit $36.54 (+97.9% upside). Prior stop was $17.17.

Q: Is ZBIO overvalued or undervalued?

Zenas BioPharma, Inc. trades at a P/E of N/A (forward -3.5). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about ZBIO?

14 analysts cover ZBIO with a consensus score of 4.4/5. Average price target: $42.

Falling Knife setup

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Sell if holding. Engine safety override at $18.38: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Elevated put/call ratio: 2.38; Below-average business quality.

$18.38+97.9% A.UpsideScore 4.9/10#89 of 158 Biotechnology

Stop $17.17Target $36.54(analyst − 13%)A.R:R 7.6:1

Analyst target$42.00+128.5%8 analysts

$36.54our TP

$18.38price

$42.00mean

$55

Passes 4/7 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and clean insider activity. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (3.3 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-3.5

Mkt Cap$1.1B

EV/EBITDA-3.1

Profit Mgn0.0%

ROE-136.2%

Rev Growth-100.0%

Beta—

DividendNone

Rating analysts14

Quality Signals

Piotroski F4/9

Options Flow

P/C2.38bearish

IV139%elevated

Max Pain$30+63.2% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

5 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality3.315%0.49

Growth5.015%0.75

Momentum1.410%0.14

Sentiment6.610%0.66

Insider Activity7.410%0.74

Peer Rank3.010%0.30

Technical Setup4.85%0.24

Risk Profile2.25%0.11

Catalyst2.55%0.13

Overall (Σ contributions)4.91

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume

0.0

Macd

0.1

Obv

1.0

Ma Position

2.2

Rsi

3.5

Volume distribution (falling OBV)Below 200-MA but MA still rising (+6.7%/30d) — pullback in uptrend, not confirmed weakness

Volatile — 6.5% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover

0.0

Volatility

0.0

Put Call

0.0

Implied Vol

0.0

Short Interest

1.0

Max Pain Risk

7.0

Debt Equity

7.7

High short interest justified: 25%Elevated put/call: 2.38High IV: 139%

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 1B/3MEarnings in 14 days

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.0

Growth Rank

0.0

Value Rank

5.0

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Net Margin

0.0

Fcf Quality

0.0

Rule Of 40

3.0

Piotroski F

4.4

Moat

5.0

Current Ratio

7.4

Gross Margin

10.0

Cash-burning: FCF -1431% of revenueNo competitive moatRule of 40: -1531 (fail)

GatesMomentum 1.4<4.5INSIDER 0.80%=EXTREMEEARNINGS PROXIMITY 14d<=14d (soft)A.R:R 7.6 ≥ 1.5No SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARFalling KnifeSuitability: Aggressive

RSI

38 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $17.39Resistance $23.00

Price Targets

$17

$37

A.Upside+98.8%

A.R:R7.6:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (3.3 < 4.0)

! Momentum score 1.4/10 — below 4.5 minimum

! Insider activity: 0.80%=extreme

Earnings

1/4 beats

Next Earnings2026-05-14 (14d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is ZBIO stock a buy right now?

Sell if holding. Engine safety override at $18.38: Quality below floor (3.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Elevated put/call ratio: 2.38; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Prior stop was $17.17. Score 4.9/10, moderate confidence.

What is the ZBIO stock price target?

Take-profit target: $36.54 (+97.9% upside). Prior stop was $17.17. Stop-loss: $17.17.

What are the risks of investing in ZBIO?

Quality below floor (3.3 < 4.0).

Is ZBIO overvalued or undervalued?

Zenas BioPharma, Inc. trades at a P/E of N/A (forward -3.5). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about ZBIO?

14 analysts cover ZBIO with a consensus score of 4.4/5. Average price target: $42.

What does Zenas BioPharma, Inc. do?Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of...

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.